Evaluation of the Lysophosphatidic Acid Receptor Type 1 Radioligand ^sup 11^C-BMT-136088 for Lung Imaging in Rhesus Monkeys

• Published in: The Journal of nuclear medicine (1978) Vol. 59; no. 2; p. 327
• Main Authors: Gallezot, Jean-Dominique, Nabulsi, Nabeel B, Holden, Daniel, Lin, Shu-Fei, Labaree, David, Ropchan, Jim, Najafzadeh, Soheila, Donnelly, David J, Cao, Kai, Bonacorsi, Samuel, Seiders, Jon, Roppe, Jeffrey, Hayes, Wendy, Huang, Yiyun, Du, Shuyan, Carson, Richard E
• Format: Journal Article
• Language: English
• Published: New York Society of Nuclear Medicine 01.02.2018
• Subjects: Binding; Biphenyl; Blood volume; Carbonyls; Carboxylic acids; Cell migration; Cell proliferation; Computed tomography; Cyclopropane; Dosimeters; Dosimetry; Drug delivery; Drug development; Equilibrium; Equilibrium analysis; Fibrosis; In vivo methods and tests; Liver; Lung diseases; Lungs; Lysophosphatidic acid; Medical imaging; Medical research; Monkeys; Monkeys & apes; Positron emission; Receptors; Saturation; Signaling; Tomography
• ISSN: 0161-5505; 1535-5667

The lysophosphatidic acid receptor type 1 (LPA1) is 1 of 6 known receptors of the extracellular signaling molecule lysophosphatidic acid. It mediates effects such as cell proliferation, migration, and differentiation. In the lung, LPA1 is involved in pathways leading, after lung tissue injury, to pulmonary fibrosis instead of normal healing, by mediating fibroblast recruitment and vascular leakage. Thus, a LPA1 PET radiotracer may be useful for studying lung fibrosis or for developing LPA1-targeting drugs. We developed and evaluated the radiotracer 11C-BMT-136088 (1-(4'-(3-methyl-4-(((1(R)-(3-11C-methylphenyl)ethoxy)carbonyl)amino)isoxazol-5-yl)-[1,1'-biphenyl]-4-yl)cyclopropane-1-carboxylic acid) in rhesus monkeys to image LPA1 in the lung in vivo with PET. Methods: The study consisted of 3 parts: test-retest scans; self-saturation to estimate the tracer's in vivo dissociation constant, nondisplaceable volume of distribution (VND), and nondisplaceable binding potential (BPND); and dosimetry. In the first 2 parts, the radiotracer was administered using a bolus-plus-infusion protocol, the arterial input function was measured, and the animals underwent 2 scans per day separated by about 4 h. Lung regions of interest were segmented, and the tissue density estimated, from CT images. A fixed blood volume correction was applied. The tracer volume of distribution (VT) was estimated using multilinear analysis 1 (MA1) or equilibrium analysis (EA). Results: 11C-BMT-136088 baseline VT was 1.83 ± 0.16 (MA1, n = 5) or 2.1 ± 0.55 (EA, n = 7) mL of plasma per gram of tissue in the leftand right lung regions of interest, with a test-retest variability of -6% (MA1, n = 1) or -1% ± 14% (EA, n = 2). For the self-saturation study, 11C-BMT-136088 VND and BPND were estimated to be 0.9 ± 0.08 mL of plasma per gram of tissue and 1.1 ± 0.14, respectively. The unlabeled drug dose and plasma concentration leading to a 50% reduction of 11C-BMT-136088 specific binding were 73 ± 30 nmol/kg and 28 ± 12 nM, respectively. The average plasma free fraction was 0.2%; thus, the tracer's in vivo dissociation constant was estimated to be 55 pM. For the dosimetry study, the highest organ dose was in the liver (43.1 ± 4.9 and 68.9 ± 9.4 µSv/MBq in reference human male and female phantoms, respectively), and the effective dose equivalent was 6.9 ± 0.6 and 8.7 ± 0.6 µSv/MBq, respectively. Conclusion: Specific binding of 11C-BMT-136088 can be reliably measured to quantify LPA1 in the lungs of rhesus monkeys in vivo.